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Abstract
The aim of the study was to establish correlation between the grade of cachexia and possible endocrine and
non endocrine factors and the type of therapy (NSAID, corticosteroids, progestagens). 98 patients aged 36–
–70 years (mean— 55 years) with various degree of cancer cachexia were qualified to the study. Statistically
significant, positive correlation between weight loss and: anorexia (p < 0.01), pain intensity (p < 0.01),
grade of depression (p < 0.01), higher values of cortisol (p < 0.05) was detected. The progestagens are the
most effective agents in the treatment of cancer cachexia, but good symptom control and psychological
status of patient are also very important.
Key words: cancer cachexia, cortisol, cytokines, progestagens
Address for correspondence: Maciej Bączyk
University of Medical Sciences, Department of Endocrinology
ul. Przybyszewskiego 49, 60–355 Poznań, Poland
Tel: +48 61 869 13 30, fax: +48 61 869 16 82
e-mail: mpd@onet.eu
Advances in Palliative Medicine 2008, 7, 9–14
Copyright © 2008 Via Medica, ISSN 1898–3863
Introduction
Cancer cachexia is mainly manifested by loss of
weight and appetite with depletion of adipose and
muscle tissue, easy satiation, general weakness, dys-
function of immune system and metabolic disor-
ders. It is present in 75% of patients with advanced
tumour. Clear diagnostic criteria of cancer cachexia
have not been established up to now [1–3]. One of
the main cachexia-inducing factors are blood pro-
inflammatory cytokines, excreted by lymphocytes and
monocytes/macrophages in response to the pres-
ence of the tumour, such as  interleukines (IL), main-
ly IL-1 and IL-6, tumour necrosis factor a (TNFa),
interferons (IFNs), mainly IFNa and IFNg. The second
group of cancer cachexia causes are tumour cata-
bolic factors i.e. lipid mobilising factor (LMF) and
protein mobilising factor (PMF) [4–7]. The third group
of cancer cachexia causes are hormonal and meta-
bolic disturbances. Dysfunction of carbohydrates me-
tabolism results in an increase in aminoacid and
lactate gluconeogenesis, activation of the Cori cy-
cle, increase in glucose metabolism, changes in in-
suline concentration, insuline resistance with in-
creased glucose intolerance. Main protein metabo-
lism disturbances are as follows: increased muscle
tissue metabolism, increased total protein metabo-
lism with the growth of acute phase proteins syn-
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thesis and decrease in muscle proteins biosynthesis.
Lipid metabolism changes include decrease in lipo-
genesis, increase in lipolysis, decrease in lipoprotein
lipase activity, increase of glycerol and hyperlipi-
daemia levels [1–4, 9].
Anorexia i.e. appetite disturbances and decreased
food intake is one of the most common symptoms
in patients with cancer cachexia. The most impor-
tant factor of anorexia development is the upset
balance between hunger and satiation processes.
Satiation and hunger centres are stimulated by the
orexogenic factors mainly by the neuropeptide Y
(NPY) and anorexogenic factors mainly by leptin and
also insulin, urocortin, glucagon-like peptide (GLP-1)
and a melanocortin (aMSH) [9, 10].
It is proved that in patients with advanced tu-
mours high level of cytokines concentration may
mimic the activity of leptins in the hypothalamus
stimulating the feeling of satiation, increase the CRF
(corticotropin releasing factor) and serotonin secre-
tion and simultaneously inhibit factors connected
with NPY such as galanin, MCH (melanin-concen-
trating hormone), oxerin and opioid peptides. Local
tumour interaction and other causes of fast satia-
tion and eating discouraging symptoms (such as
nausea, vomits, pain etc.) or psychodepresive disor-
ders (occuring in 20–60% patients with advanced
cancer), may significantly influence the appetite
[1, 4, 8].
It is worth considering that in most of patients
the intensity of anorexia may be inadequatly low in
comparison with the degree of the cachexia.
Fast progressing cachexia leads to anaemia, mal-
nutrition, loss of muscle mass and loss of activity,
disturbances of internal organs and immune system
functions, changes of the appearance, depression,
poorer social contacts, worse quality of life, and in
the end to the faster death of the patient. In cachex-
ia treatment various drugs are being applied. Posi-
tive effects have been proved for: progestagens, glu-
cocorticoids and prokinetics. In some cases adju-
vant drugs such as antidepressants, non-steroid anti-
inflammatory drugs (NSAID), anabolic steroids and
cannabinoids may also have positive action. Partici-
pation of following factors: thalidomide, b2-mimet-
ics, ghrelin, anabolic cytokine analogues, anti-TNFa
antibodies, drugs anti-NFkb, somatotropin/ IGF is
still under investigation [2, 7, 10].
Aim of the study
The aim of the study was to establish correlation
between the degree of cachexia and diagnosed en-
docrine disorders which may influence metabolic
processes as well as a potential influence of the
applied treatment on studied parameters and gen-
eral status of the patients.
Material and methods
98 patients aged 36–70 years (mean — 55 years)
with various degree of cancer cachexia were quali-
fied to the study. Patients with confirmed presence
of coexisting acute or exacerbated inflammation,
like purulent changes and decubitus etc. were ex-
cluded from the study group. All of the patients
were able to eat normally. In all patients basic bio-
chemichal tests were performed and chosen hor-
monal parameters: diurnal cortisol rhythm, thyroid
hormones (FT4, FT3, rT3) and thyreotropin level (TSH),
insulin level, IGF-1, cytokines levels (IL-6, TNFa). Sex
hormones levels were not measured due to the wide
range of age of the patients. The investigations were
performed with the consent of the patients during
routine biochemical blood tests. Symptoms control
card was used. It allowed to assess the correlation
between other factors (VAS scale pain control, de-
pression and anxiety degree in HADS scale, loss of
appetite, nausea, decrease of efficiency in 100-de-
gree Karnofsky scale) which may cause cachexia.
The study protocol included information concern-
ing the course of the disease and the latest caus-
ative and symptomatic treatment. In the statistical
analysis, the Shapiro-Wilk test was used to assess
the distribution normality of the tested variables. In
case of normal distribution, Student t-test and vari-
ance analysis with repeated measurements with Bon-
feroni test were used. For variables without normal
distribution the differences were evaluated with the
use of Mann-Whitney test and Friedman test with
Dunn test for multiple comparisons. Correlation of
variables with normal distribution was tested with
the use of Pearson correlation coefficient, in case of
other variables — with the use of Spearman correla-
tion coefficient. The hypotheses were verified with
the significance level a = 0.05.
Patients were divided into four groups:
group I — 25 patients with newly diagnosed ad-
vanced cancer and cancer cachexia symptoms
(without complex symptomatic treatment);
group II — 25 patients with cancer cachexia treated
symptomatically* with non-steroid anti-inflam-
matory drugs (treated systematically longer than
4 weeks);
group III — 23 patients with cancer cachexia treated
symptomatically* with glucocorticoids — dex-
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amethasone 4 mg daily (treated systematically
longer than 4 weeks);
group IV — 25 patients with cancer cachexia treat-
ed symptomatically with progestagens — mege-
strol 800 mg daily (treated systematically longer
than 4 weeks).
*symptomatic treatment means that there exis-
ted additional significant (other than cachexia) indi-
cations for NSAIDs or glucocorticoids.
The study group included patients with tumours
of the abdomen (colorectal cancer, pancreatic can-
cer, ovarian cancer). In all the groups (I–IV) the dis-
tribution of the tumours among the patients was
similar. The control group consisted of 30 healthy
people.
Results
In the hormonal tests most of the patients pre-
sented high cortisol level without diurnal rhythm,
disturbances of T4 conversion to T3 (low T3 syn-
drome) with elevated rT3 levels, low fasting insulin
levels and lowered IGF-1 level. TNFa and IL-6 levels
were elevated. In the studied group statistically sig-
nificant positive correlation between body weight
loss and loss of apetite (p < 0.01), worse pain con-
trol (p < 0.01), severity of depression (p < 0.01),
elevated cortisol level (p < 0.05) was proved. Treat-
ment efficacy with all drug groups described above
(later these drugs were used in combination) was
the lowest in patients with low Karnofsky score and
with large initial weight loss. Despite the tendency,
the weight loss did not correlate statistically signifi-
cant with TNFa (p = 0.09) and IL-6 (p = 0.06) levels.
Laboratory tests in most of the patients revealed
moderate anaemia, moderate hypoproteinaemia,
lack of significant electrolite disturbances and gly-
caemia regulation disorders (tendency to the retar-
dation of postprandial insulin peak and insulin resis-
tance). Elevated cortisol level correlated negatively
with the lower performance status in the Karnofsky
scale (r = –0.4, p < 0.05) and positively, with the ape-
tite loss (statistically insignificant; p = 0.06, r = 0.3).
In two patients with fast progression of weight loss
hyperthyroidism was diagnosed; high fT4 and fT3
levels and lowered TSH level < 0.05 µU/ml (probably
hyperthyroidism was induced by the intake of vita-
mins preparation with high iodine content). Patients
Table 1. Encompassing results of the study (median values rating)
Parameters Control  Group I Group II Group III Group IV
(median) group
Weight loss
Last 6 months (%) 0 –20 –22 –20 –23
Last month (%) — during therapy 0 –5 –4 0 +3
Haemoglobinn (12–16 g/dl) 14.2 11.3 10.9 10.6 11.0
TNFa (n. < 12 pg/ml) 10 69 45 33 38
IL-6 (n. < 31 pg/ml) 23 318 235 80 98
Cortisol at 8.00 a.m.
(n. 350–650 pmol/l) 472 738 700 215 450
Cortisol (06.00 p.m.)
(n. 120–270 pmol/l) 160 522 492 194 288
FT4 (n. 9–21 pmol/l) 15.0 17.0 16.8 13.9 15.1
FT3 (n. 4–8 pmol/l) 6 4.3 4.1 3.9 4.5
rT3 (n. 9–35 ng/dl) 24 58 65 66 62
TSH (n. 0.3–3.5 mU/ml) 1.1 1.8 1.6 1.2 1.5
Anorexia (0–3) 0 1.5 1.5 0.5 0
Pain intensity (VAS 0–10) 0 5 3 2 2
Depression (HADS scale) 3 9 7 6 5
0–7 norm 100% 40% 53% 53% 60%
8–10 border values 20% 20% 20% 20%
11–-21 depression 40% 27% 27% 20%
Anxiety (HADS scale) 3 10 9 7 7
0–7 norm 100% 40% 40% 53% 53%
8–10 border values 20% 20% 20% 21%
11–21 pathologic anxiety 40% 40% 27% 26%
Karnofsky’s scale (100–0) 100 50 60 60 60
TNFa — tumor necrosis factor alpha; IL-6 — interleukin 6; FT3 — free triiodothyronine; FT4 — Free Thyroxine; rT3 — reverse triiodothyronine;
TSH — thyrotropin; VAS — visual analogue scale; HADS — Hospital Anxiety and Depression Scale
Advances in Palliative Medicine 2008, vol. 7, no. 1
www.advpm.eu12
treated with non-steroid anti-inflammatory drugs,
glucocorticoids and progestagens in most cases
showed increased and statistically significant lower
levels of interleukines and TNFa (p < 0.05) in com-
parison to the patient not treated with these drugs.
The results are presented in Table 1.
Discussion
The results indicate that cancer cachexia is influ-
enced by many factors among which the endocrine
system plays vital role. Chronic stress caused by the
cancer causes prolonged activation of subthalamus-
pituitary-adrenals axis and impairment of the reflex-
ive inhibition in this axis. This mechanism is similar
to the one observed in depressive disorders. Exces-
sive CRF production and excretion, adaptive decrease
of ACTH response to the CRF level, decrease of num-
ber and sensitivity of glucocorticoid receptors are
the effects of aforementioned mechanisms. Persis-
tently decreased CRF level is connected with the low
mood, intensification of the anxiety-depressive re-
action, sleep and apetite disorders (potential indica-
tion for the adjuvant therapy with antidepressants
in approximately 40–60% patients) [2–4, 11]. Chronic
hypercortisolism causes catabolism of proteins, li-
polysis, increased gluconeogenesis. Together with
high cytokines levels hypercortisolism induces insu-
lin resistance, causing tendency to postprandial hy-
perglycaemia inhibiting apetite after intake of small
amount of food [12–14]. The results as well as the
literature data indicate that use of NSAIDs, gluco-
corticoids or progestagens, may significantly de-
crease concentration of cytokines, especially of TNFa
that is vital in cachexia. On the one hand TNFa in-
creases secretion of ACTH, on the other activates
NFkb which inhibits the synthesis of MyoD protein
(Myogenic regulatory factor D). MyoD deficiency is
a cause of inhibition of formation and diferentiation
of muscle tissue which causes musle atrophy and
cachexia. To date no effective TNFa inhibiting drug
has been developed. It is possible that NFkb will be a
trigger point for a new generation of drugs [15–18].
Clinical observation indicate that cachexia correlates
more with the duration of high cytokines levels than
with their sporadically measured absolute values.
Degree of production inhibition of IL and TNFa var-
ies between the drugs: it is the highest in case of
glucocrticoids, slightly lower for progestagens and
the lowest for NSAIDs. An advantage of progestagens
lies in their partial resemblance to the glucocorti-
coids in the anti-inflammatory effect without coex-
isting significant catabolic effect especially on the
muscle tissue observed in case of prolonged admin-
istration of dexamethasone [19, 20]. Reduction of
cytokine concentration irrespective of the applied
treatment decreases their leptin-like inhibitory ef-
fect on appetite. Physiological cortisol profile may
significantly influence the reduction of depressive
disorders tendency. During Megestrole therapy it
must be remembered that prolonged high doses
administration may permanently inhibit the hypo-
thalamus–pituitary–adrenals axis. Attempting to re-
duce the disorders causing cancer cachexia, symp-
tomatic treatment must be performed; mainly man-
aging pain, nausea, vomiting and other factors lead-
ing to anorexia. Trials of intensive parenteral ali-
mentation, especially if there is a possibility of regu-
lar, oral food intake, in most advanced cases are
ineffective and sometimes decrease comfort of ther-
apy [21–23]. Cancer cachexia treatment should base
on the analysis of different clinical parameters. Phar-
macological treatment should aim at the good con-
trol of the symptoms and improvement of psycho-
logical condition of the patient. Final conclusions of
our studies may be modified due to the relatively
low number of patients and restricted spectrum of
cancer diseases included in the study.
Conlusions
1. Cancer cachexia results from many different fac-
tors. One of the most significant factors is par-
tially disordered function of the endocrine sys-
tem, especially the hypothalamus — pituitary
— adrenals axis.
2. The highest efficiency of cancer cachexia treat-
ment is provided by complex therapy with good
control of symptoms, progestagens administra-
tion (together with other cytokine inhibiting
drugs), antidepressant therapy of selected cases.
3. Efficacy of cachexia syndrome therapy decreases
with the increase of the disease stage and with
the deterioration of the general status.
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